Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 10, 2020 1:26pm
146 Views
Post# 32077811

RE:RE:RE:RE:Timing of trials

RE:RE:RE:RE:Timing of trialsI wish you were right but since that article came out after the end of the fiscal year, ,Paul must be referring to the calendar year end when he spoke about being committed to getting those protocols in by the end of the year. If not, he would have said that they successfuly achieved their objective already, right?

palinc2000 wrote:

Q-1 has to mean THTX Q-1 Not calendar year Q-1

 

SPCEO1 wrote: I have an easy fix for that - TH should change its reporting to a calendar year end from November year end. For analysts, it makes life so much easier.

Meanwhile, I think you can assume that he is using normal calendar terminolgy and not fiscal year terminology. But I could be wrong about that as they are not always consistent on that and it has caused me some confusion in the past too.
 

 

SABBOBCAT wrote: I think Paul and TH need to be clearer in their communication. Right now it seems they may be mixing terminology that clouds the picture for those of us looking to establish a timeline. In reading the terms "year end" or "in Q1", I would interpret that as fiscal year terminology that refers to November YE and February Q1. On the other hand specifics of before the end of December 2020 or March 2021 should be used if they are referencing the calendar year. If they are using the terms properly and are referring to the fiscal year, they should have filed the INDs and the trials should start before February

 




<< Previous
Bullboard Posts
Next >>